MissionIR today released its
interview with CytRx Corp. President and Chief Executive Officer Steven
Kriegsman, as well as the company’s vice president of business development and
investor relations David Haen. The full audio interview is available at the
following link: http://CYTR.MissionIR.com/interview-jan2014.html.
CytRx is a biopharmaceutical
R&D company developing cancer drugs for several indications. The company’s
lead candidate, aldoxorubicin, is the company’s improved formulation of widely
used chemotherapy agent, doxorubicin. Phase 2b study results, released in
December 2013, showed aldoxorubicin to be superior to doxorubicin by both an
investigator assessment and a central lab review. Furthermore, aldoxorubicin
was found to be safe and well-tolerated with no treatment-related deaths.
Speaking with MissionIR host
Stuart Smith, CEO Kriegsman explained in depth the tremendous value of the
results.
“We really had spectacular
results in our global phase 2b clinical trial in first-line soft tissue
sarcoma. And when I say ‘spectacular,’ they were highly statistically
significant, not just statistically significant… we had great response rates…
we saw substantial tumor shrinkage,” Kriegsman said.
The trial results triggered
a triple-digit rally in CytRx stock, adding to a year of gains. As Kriegsman
put it, “It was a wonderful year for CytRx, it was a wonderful year for our
shareholders, but most importantly it was a wonderful year for sarcoma patients
who were privileged to get aldoxorubicin rather than doxorubicin.”
Haen added that
aldoxorubicin in the head-to-head study not only met the primary endpoints, it
also opened the door for additional therapeutic applications.
“This data is quite robust…
this really paves the way that aldoxorubicin is superior to doxorubicin. Now we
can look for the next trials with soft tissue sarcoma, but we can also have
greater confidence in expanding to other indications where doxorubicin is used
because we’ve shown that [aldoxorubicin] is superior,” added Haen.
While 2013 was a powerful
year for CytRx in many ways, Kriegsman said it “pales in comparison to what we
expect to achieve in 2014,” and further embellished on upcoming events and
expectations, including an agreement with the FDA, additional clinical trials,
possible partnerships and other significant milestones.
For more information, visit
www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
